Trimetazidine

Mitochondrial Disease

Steen Hvitfeldt PoulsenSmall moleculePhase 4 / ApprovedActive

BB

69/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 54/ 100
Competitive Position: 95/ 100

Competitive context

8 Active assets in the Mitochondrial Disease cohort.

Asset / Sponsor	Phase	Rating
Sonlicromanol Khondrion BV	Phase 3	BB
Sodium Chloride University Hospital, Strasbourg, France	Phase 4	BB
ARG University Hospital, Strasbourg, France	Phase 4	BB
Efavirenz The Cleveland Clinic	Phase 4	BB
NORVIR The Cleveland Clinic	Phase 4	BB

View all 16 →

Same molecule, other indications

Trimetazidine is also rated in:

hepatocellular carcinomaDormant

B

Indicative · Phase 3

57 / 100

metabolic dysfunction-associated steatotic liver diseaseActive

B

Indicative · Phase 2

57 / 100

ischemic strokeActive

CCC

Indicative · Phase 3

54 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.